亚胺培南／西司他丁钠与美罗培南治疗重症感染的成本-效果分析

Cost-effectiveness analysis on Imipenem-Cilastatin Sodium and Meropenem for severe infection

目的评价亚胺培南／西司他丁钠（IMP）与美罗培南（MEP）治疗重症感染的经济学效果。方法运用最小成本分析法，分别对上述2种治疗方案治疗重症感染的临床效果及成本进行评价。结果亚胺培南／西司他丁钠组和美罗培南组治疗重症感染的总有效率分别为93．33％（28／30）和85．71％（24／28），差异无统计学意义（χ^2=4．89，P=0．08）；成本-效果比（C／E）分别为40．35和71．69，与亚胺培南／西司他丁钠组相比，美罗培南组每增加一个单位效果需多花费（△C／AE）312．16元。结论亚胺培南／西司他丁钠组的成本-效果比优于美罗培南组，亚胺培南／西司他丁钠治疗重症感染有明显的药物经济学优势。

Objective To evaluate the economic effects of Imipenem-Cilastatin Sodium and Meropenem for severe infection. Methods The therapeutic effects and costs of the two therapeutic schemes for severe infection were evaluated by using cost-minimization analysis. Results The total effective rates of Imipenem- cilastatin group and Meropenem group in the treatment severe infection were 93.33% （28/30） and 85.71% （24/28）, the difference were not statistically significant （ χ^2 = 4. 89, P = 0. 082 ）. The cost-effectiveness ratio （C/E） were 40. 35 and 71.69 respectively. The cost of every unit increment of effectiveness for Meropenem group were 312. 16 Yuan,more than that of the Imipenem-cilastatin group. Conclusion Cost-effectiveness ratio of Imipenem-cilastatin is superior to that of Meropenem, and Imipenem-cilastatin has obvious pharmacoeconomics advantage over Meropenem for severe infections.